Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback
FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
Spire Wealth Management Acquires New Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)
Spire Wealth Management bought a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) in the fourth quarter, ...
Tenaya Therapeutics receives $8M clinical grant from CIRM
Tenaya Therapeutics (TNYA) announced that the California Institute for Regenerative Medicine, CIRM,, a state of California Agency that funds ...
Nasdaq14d
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days ...
Investing14d
Tenaya Therapeutics announces option repricing to retain staff
In a move to motivate and retain its employees, Tenaya Therapeutics , Inc. (NASDAQ:TNYA), a biotechnology firm specializing in biological products, has announced the repricing of certain stock options ...
Nasdaq14d
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...